Acute megakaryoblastic leukemia in Down syndrome

Citations Over TimeTop 15% of 2007 papers

Abstract

Children with Down syndrome (DS) have a 10- to 20-fold increased risk of developing acute leukemia. An estimated 10% of newborns with DS develop Transient Myeloproliferative Disease (TMD) or Transient Leukemia (TL), a clonal accumulation of megakaryoblasts that resolves spontaneously within months. Acute megakaryoblastic leukemia (AMKL) develops in approximately 20% of cases of TMD/TL by 4 years of age. Both the blasts of AMKL and TMD/TL in DS harbor somatic mutations of GATA1, an essential transcriptional regulator of megakaryocytic differentiation. The distinct phenotypes of megakaryoblastic leukemia in DS are a unique biological model of the incremental process of leukemic transformation.

Related Papers

• → GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome(2003)324 cited
• → Down syndrome and leukemia: insights into leukemogenesis and translational targets.(2015)84 cited
• → Megakaryoblastic Leukemia and Down's Syndrome: A Review(1987)134 cited
• → Evolution of myeloid leukemia in children with Down syndrome(2016)16 cited
• → Distinct Clones are Associated with the Development of Transient Myeloproliferative Disorder and Acute Megakaryocytic Leukemia in a Patient with Down Syndrome(2007)6 cited